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Herein, we describe the development of a novel staple with an 
electrophilic warhead to enable the generation of stapled peptide 
covalent inhibitors of the p53-MDM2 protein-protein interaction 
(PPI). The peptide developed showed complete and selective 
covalent binding resulting in potent inhibition of p53-MDM2 PPI.
Targeted covalent inhibitors (TCIs) are a class of molecules 
that have been increasing in popularity and are reviving the 
field of covalent inhibitors.1 TCIs employ weak electrophile 
warheads in their structure that, upon ligand binding, can 
react with a nucleophilic residue of the target protein. This 
results in a more controlled and selective binding towards the 
site of interest. The covalent bond only forms when the 
“warhead” is brought into close proximity of the appropriately 
located nucleophilic residue as a consequence of the inhibitor 
binding to the designed pocket.1a Compared to non-covalent 
inhibitors, TCIs can offer several advantages which include the 
potential for improved potency,2 longer duration of action,3 
improved selectivity, and the possibility for inhibiting 
‘intractable’ targets.1a,4,5
Most covalent inhibitors have been designed to target a 
cysteine residue near the substrate binding site due to its low 
abundance in the proteome and its unique reactivity.6 
However, not all binding sites contain cysteine residues in the 
ideal proximity.7 Lysine is more ubiquitous than Cys and has 
been targeted in a wide variety of biological systems;1b,7 
however, examples of inhibitors targeting surface-exposed 
lysine are rare. The challenge for targeting the ε-NH2 group of 
Lys is its high pKaH (10.4) which renders 99.9% of the amino 
group protonated under physiological conditions.8 
Nonetheless, surface-exposed lysine can be targeted following 
a careful design.1h
MDM2, an E3 ubiquitin ligase, is a negative regulator of the 
tumour suppressor p539 and ubiquitination of p53 limits its 
activity.10 Approximately 50% of human cancers possess 
mutated p53, whilst others overexpressed MDM2 resulting in 
the malignant cells being able to escape apoptosis.11 
Therefore, inhibition of the p53-MDM2 PPI presents a 
potential target for cancer therapy as documented by at least 
10 compounds currently in clinical trials.12
Because PPIs generally have relatively large and shallow 
binding pockets,13 peptides are a suitable choice for inhibiting 
them due to their greater contact surface area, similar to 
native proteins, compared to small molecules. However, 
peptides on their own may suffer from poor proteolytic 
stability and bioavailability.14 One of the most successful 
approaches to inhibit PPIs and overcome the intrinsic 
limitations of peptides is the use of stapled peptides – e.g. 
peptides constrained into their binding conformation by 
chemically cross-linking two amino acid side chains.14a,c,d In the 
case of the p53-MDM2 PPI, several stapled peptides have been 
developed with one example, ALRN-6924, reaching phase II 
clinical trials.14b,d,15
A recent example of a TCI is the stapled peptide mSF-SAH, 
which was developed to target the p53-MDM2/4 protein-
protein interaction (PPI) covalently.16 Hoppmann and Wang 
incorporated an unnatural amino acid with an electrophilic 
sulfonyl fluoride group into the peptide sequence targeting a 
lysine or histidine residue near the binding site on MDM2/4; 
one-component peptide stapling was then used to constrain 
the peptide (Scheme 1a).16
Inspired by the work of Hoppmann and Wang,16 we 
proposed to utilise the non-covalent binding of a stapled 
peptide to bring the electrophile into proximity of the targeted 
surface-exposed Lys residue near the MDM2 binding site. 
Thus, the covalent ligand-protein cross-linking is facilitated via 
proximity-enabled bioreactivity (Scheme 1b).17 The resulting 
covalent linkage would prevent peptide dissociation and 
provide better inhibitory activity. Unlike previous reports, we 
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envisioned to introduce the electrophilic warhead on a staple 
core compatible with the copper-catalysed azide-alkyne 
cycloaddition two-component peptide stapling (CuAAC 2C-
PS).14d The use of 2C-PS improves the efficiency of the 
optimisation process as each variation of the staple does not 
require a completely new synthesis of each peptide.18 
Moreover, CuAAC 2C-PS provides mild conditions with 
reactions conducted at room temperature in aqueous solution 
and are compatible with unprotected peptides. We envisaged 
that by placing the electrophile on the staple and utilising a 2C-
PS approach, simpler proximity tuning, staple screening, and 
synthesis can be achieved (Scheme 1b). 
Initial analysis of the binding site of MDM2 (PDB code: 
5AFG)15d suggested that the solvent-exposed Lys94 may be a 
feasible residue for covalent targeting (Fig. 1a). Molecular 
modelling methods were used to determine the optimal 
peptide sequence, staple position, and staple structure for 
covalent binding with Lys94.19 We decided to adopt the phage-
derived peptide PMI sequence (H-TSFAEYWNLLSP-OH) as the 
basis for our stapled peptide because it offers strong MDM2 
binding ability and good aqueous solubility.20 We employed 
the same azido-ornithine amino acid and 1,3-diethynylbenzene 
staple (4, Fig. 1b) that were used by Lau et al. for i, i + 7 2C-PS 
in our molecular models,14b which showed that the optimal 
staple positions are at residues 5 and 12, such that an 
electrophilic group at the 5-position of the staple could come 
into close contact with Lys94. Leu9 was mutated to Gly to 
prevent steric clash of the side chain with the staple (Fig. S1, 
ESI†). As a result, the peptide P1 was identified as the optimal 
sequence to position the electrophilic staple in the correct 
location for targeting Lys94 (Fig. 1c).
We chose a sulfonyl fluoride and two activated esters for 
initial screening of possible electrophiles (Fig. 1b). The sulfonyl 
fluoride electrophile (1) was selected based upon previous 
reports of its resistance to reduction, hydrolysis, and 
exclusivity to heterolytic cleavage.21  In addition, its biological 
application has been demonstrated through a plethora of 
examples including peptidic and Lys-targeted small-molecule 
binders.16,22 Whereas, activated esters, namely 
sulfotetrafluorophenyl (STP) ester (2) and 2,4-dinitrophenyl 
ester (3), were chosen due to their harder electrophilic 
character which makes them more susceptible to an attack by 
an amine relative to a thiol. Moreover, activated esters are 
validated probes for proteomic profiling for lysine reactivity.23 
Molecular dynamics simulations showed that the ester and 
sulfonamide covalent complexes of the two-component 
stapled P1 with Lys94 of MDM2 are stable, with the three key 
binding residues of the peptide (Phe3, Trp7, and Leu10) 
remaining bound within the p53-binding cleft at the end of all 
simulations (Fig. S1, ESI†).
Considering these data, we designed compounds 1-3 as 
potential electrophile-containing staples (Fig. 1b). Staples 1, 2, 
and 3 were then synthesised and tested for their compatibility 
with the CuAAC 2C-PS,18 stability in aqueous media, and 
reactivity towards lysine. Compound 3 was insoluble in 
aqueous conditions; thus, it was excluded from further testing. 
Despite the comparable stability of staples 1 and 2 in 
physiological pH (49% intact for 1 vs 42% for 2 after 24 h, Fig. 
2a), activated ester 2 was progressed as it was found to be 
significantly more stable under the CuAAC 2C-PS conditions 
(15% intact for 1 vs 83% for 2 after 24 h, Fig. 2b). In addition, 2 
showed a faster reactivity with Lys whilst 1 mostly underwent 
Fig. 1 a) Molecular dynamics simulation of PMI-derived stapled peptide (red) 
covalently linked with MDM2 (grey) through amide bond with Lys94 close to the 
binding site. b) The structures of the proposed staples: aryl sulfonyl fluoride 1, 
sulfotetrafluorophenyl (STP) ester 2, and dinitrophenyl ester 3. The non-electrophilic 
staple 4 was used as a control. c) The optimal linear diazidopeptide P1.
Scheme 1 a) Previous work using one-component stapling and incorporation of an 
electrophilic moiety into the peptide sequence for generating a stapled peptide 
covalent inhibitor for MDM2/4.16 Covalent-crosslinking occurs through proximity-
enabled bioreactivity.17 Shaded circle denotes resin. Nu = Lys or His b) Utilising 2C-PS 
for generation of stapled peptide covalent inhibitors. Structure of P1-2, the developed 
stapled peptide covalent inhibitor, is shown.
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hydrolysis (5% Lys-conjugated for 1 vs 95% for 2 after 4 h, Fig. 
2c). With these results in hand, we decided to take forward the 
STP ester 2 as our electrophile-containing staple. The 
optimised peptide P1 was stapled with compound 2 to obtain 
the stapled peptide P1-2 (Scheme S1, ESI†). Pleasingly, circular 
dichroism measurements confirmed the staple used was able 
to enhance the α-helical conformation of the peptide (12% for 
P1 vs 22% for P1-2, Fig. S2, ESI†). 
In order to assess the ability of P1-2 to form a covalent 
complex with MDM2, P1-2 was incubated with MDM2 and the 
reaction mixture analysed by mass spectrometry (Fig. 3). After 
the incubation, complete formation of the covalent complex 
was observed and no unmodified MDM2 remained (Fig. 3a-b). 
Pleasingly, by replacing P1-2 with the control peptide P1-4 (no 
electrophilic moiety, Scheme S1, ESI†), detection of a covalent 
peptide-MDM2 complex was not observed (Fig. S3, ESI†).
Under the same conditions, mass spectrometry results of 
the STP ester 2 alone (i.e. without peptide) with MDM2 
resulted in only a small amount of the protein being modified, 
therefore highlighting the importance of the specific non-
covalent binding of P1-2 to MDM2 for the cross-linking event 
to occur (Fig. 3c). 
The selectivity of the stapled peptide was investigated 
further by the addition of human lysozyme (Lyz) to the 
incubation. Lyz contains five highly solvent-accessible lysine 
residues out of which, one is particularly active.24 Following 
the incubation, formation of the peptide-lysozyme covalent 
complex was not detected indicating that P1-2 selectively 
binds MDM2 (Fig. S4).
Finally, the apparent dissociation constant (Kd,app) of P1-2 
to MDM2 was examined and compared to the non-covalent 
peptides using a competitive fluorescence polarisation (FP) 
assay (Fig. 4).14b,15c The linear diazidopeptide P1 was found to 
have an attenuated dissociation constant for MDM2 (Kd = 47.8 
± 1.5 nM, Fig. 4a) compared to the wild-type (WT) PMI (Kd = 
16.6 ± 0.2 nM, Fig. 4a).20 Pleasingly, the stapled peptide P1-4 
showed an affinity comparable to the WT (Kd = 19.3 ± 0.3 nM, 
Fig. 4a). Crucially, over the course of 120 minutes, these 
dissociation constants did not change significantly (Fig. 4b, S5-
6, ESI†). In contrast, as expected for a TCI, the apparent 
dissociation constant of P1-2 improved over time as the 
covalent bond was formed, ultimately resulting in a potent 
MDM2 inhibitor after 120 minutes (Kd,app = 30.0 ± 9.2 nM at 9 
min which decreased to 7.1 ± 2.1 nM at 120 min, Fig. 4c-d).25,‡ 
 In summary, we have developed a novel strategy for 
producing stapled peptide covalent inhibitors. Expanding on 
a) Peptide Kd (nM)† b)
WT PMI 16.6 ± 0.2
P1 47.8 ± 1.5






9 30.0 ± 9.2
41 12.9 ± 4.1
120 7.1 ± 2.1
Fig. 2 Stability and reactivity tests of compounds 1 (red) and 2 (blue) a) Stability in 
aqueous media: PBS (1x): MeCN (1.94:1), 37 °C. b) Stability in CuAAC condition: 
tBuOH/water (1:1), 1.1 eq. of the compound (0.73 mM), CuSO4.5H2O (1 eq.), THPTA (1 
eq.) and Na-L-ascorbate (3 eq.) at rt. c) Reactivity comparison between compounds 1 
and 2 against Nα-Ac-Lys-OH. Conditions: PBS (1x): MeCN (1.94:1), 1 mM concentration 
of the compound, Nα-Ac-Lys-OH (2 eq.). E = electrophile, LG = leaving group. Solid lines 
indicate conjugation while dotted lines indicate hydrolysis. All reactions were 
monitored by analytical HPLC and caffeine was used as the internal standard. The 
results are average of two independent repeats and the errors shown as standard 
errors of mean.
Fig. 3 ESI-MS spectra for reactions with MDM2 a) the unmodified MDM2. [MDM2 + H]+ 
= 13783 Da. b) P1-2 (25 μM) was incubated with MDM2 (25 μM) in PBS buffer (+10% 
DMSO) at 37 °C for 1 h. ESI-MS spectrum of the reaction indicated the complete 
covalent binding of the stapled peptide. [MDM2 + P1-2 – STPOH + H]+ = 15400 Da c) 
The same incubation as in b) but with P1-2 replaced with compound 2. ESI-MS 
spectrum showed low reactivity of the electrophile on its own with most MDM2 
unreacted. [MDM2 + 2 – STPOH + H]+ = 13933 Da; STPOH = sulfotetrafluorophenol
Fig. 4 a) Dissociation constants for non-covalent peptides. †The Kd values are the 
average of every time point and the errors are standard errors of mean. b) Competitive 
FP assay of P1-4 showing no change in affinity over time. Each curve represents one 
time point: 9 min (red), 41 min (green), and 120 min (blue). Each data point is 
arithmetic mean of triplicate and the errors shown are standard errors of mean. c) 
Apparent dissociation constant of P1-2 at each time point. d) Competitive FP assay of 
P1-2 showing the increase of the apparent dissociation constant over time which is 
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our CuAAC 2C-PS technique, the staple was functionalised with 
a suitable electrophile for forming a covalent cross-linking with 
the target protein upon binding. We validated this approach 
using an STP ester-functionalised stapled peptide targeting the 
oncogenic protein MDM2: the lead peptide P1-2 
demonstrated complete covalent complex formation and nM 
inhibition to MDM2. 
Importantly, the results and concept of our study would 
expedite the development of stapled peptide covalent 
inhibitors by removing the need to synthesise the peptides 
anew for every sequence and requiring less demanding 
conditions on the electrophile. We envision that targeting 
proteins with low turnover rates would gain the most benefit 
from using this strategy.1a,7a A further advantage of using the 
CuAAC 2C-PS technique is that extra functionalisation may be 
achieved by appending a second functional handle to the 
staple and hence further enhance the capability of peptide 
inhibitors.
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